


This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (original): A compound of formula (I)



wherein

each R is independently selected from H or C₁-C₄ alkyl;

R¹ is H, C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, cyano, trifluoromethyl, trifluoromethoxy, -NR³R⁴, -CONR³R⁴, -COOR³ or a group of the formula

*c1ccccc1B5

(i)

R² is C₁-C₄ alkyl, phenyl or phenyl substituted with 1, 2 or 3 substituents

each independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, nitro,

hydroxy, cyano, halo, trifluoromethyl, trifluoromethoxy, benzyl,

benzyloxy, $-\text{NR}^6\text{R}^7$, $-\text{CONR}^6\text{R}^7$, COOR^6 , $-\text{SO}_2\text{NR}^6\text{R}^7$ and $-\text{SO}_2\text{R}^6$;


R⁵ is selected from H, C₁-C₄ alkyl, C₁-C₄ alkoxy, carboxy, nitro, hydroxy, cyano, halo, trifluoromethyl, trifluoromethoxy, benzyl, benzyloxy, -NR⁸R⁹, -CONR⁸R⁹, -SO₂NR⁸R⁹ and -SO₂R⁸;

R^3 , R^4 , R^6 , R^7 , R^8 and R^9 are each independently selected from H or C_1 - C_4 alkyl; and

-Z- is a bond, $-CH_2-$, or $-O-$;


or a pharmaceutically acceptable salt thereof.

2. (original): A compound as claimed in claim 1, wherein -X- is -S-.
3. (currently amended): A compound as claimed in ~~either one of claims~~ claim 1 ~~or 2~~, wherein R^2 is phenyl.
4. (currently amended): A compound as claimed in ~~any one of claims~~ claim 1 ~~to~~ 3, wherein all R groups are hydrogen.
5. (original): A compound as claimed in claim 1, represented by the formula (II)



(II)

wherein R^1 is H, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, halo, cyano, trifluoromethyl, trifluoromethoxy, $-NR^3R^4$, $-CONR^3R^4$, $-COOR^3$ or a group of the formula (i)



R^5 is selected from H, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, carboxy, nitro, hydroxy, cyano, halo, trifluoromethyl, trifluoromethoxy, benzyl, benzyloxy, $-NR^8R^9$, $-CONR^8R^9$, $-SO_2NR^8R^9$ and $-SO_2R^8$;

R^3 , R^4 , R^8 and R^9 are each independently selected from H or C_1 - C_4 alkyl;
-Z- is a bond, $-CH_2-$, or $-O-$;
or a pharmaceutically acceptable salt thereof.

6. (currently amended): A compound as claimed in ~~any one of claims~~ claim 1 to 5, wherein the substituent R^1 is in the three position of the pyridine ring as numbered in formula (I) above.
7. (currently amended): A compound as claimed in ~~any one of claims~~ claim 1 to 6, wherein R^1 is H, C_1 - C_4 alkyl, halo, cyano, $-CONR^3R^4$, trifluoromethyl or a group of the formula (i).
8. (currently amended): A compound as claimed in ~~any one of claims~~ claim 1 to 7, wherein R^1 is $-CONR^3R^4$ and R^3 and R^4 are both H.
9. (currently amended): A compound as claimed in ~~any one of claims~~ claim 1 to 7, wherein R^1 is a group of the formula (i), -Z- is a bond, and R^5 is H or halo.
10. (currently amended): A compound as claimed in ~~any one of claims~~ claim 1 to 7, wherein R^1 is a group of the formula (i), -Z- is $-CH_2-$ or $-O-$, and R^5 is H.
11. (currently amended): A compound as claimed in ~~any one of claims~~ claim 1 to 5, wherein the substituent R^1 is in the five position of the pyridine ring as numbered in formula (I) above.
12. (original): A compound as claimed in claim 11, wherein the substituent R^1 is selected from bromo, chloro or iodo.
13. (currently amended): A pharmaceutical composition, comprising a compound as claimed in ~~any one of claims~~ claim 1 to 12 or a pharmaceutically acceptable

salt thereof, together with a pharmaceutically acceptable diluent, excipient or carrier.

14. (cancelled)

15. (cancelled)

16. (cancelled)

17. (currently amended): A method for selectively inhibiting the reuptake of norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in ~~any one of claims~~ claim 1 to 12, or a pharmaceutically acceptable salt thereof.

18. (currently amended): A method for treating disorders associated with norepinephrine dysfunction in mammals selected from the group consisting of an attention-deficit disorder (ADD) due to general medical conditions, attention-deficit hyperactivity disorder (ADHD) including the predominantly inattentive type of ADHD and the predominantly hyperactive-impulsive type of ADHD, cognitive disorders including mild cognitive impairment (MCI) and cognitive impairment associated with schizophrenia (CIAS), conduct disorder, depression (including adolescent depression and minor depression), dysthymic disorder, and oppositional defiant disorder, comprising administering to a patient in need thereof an effective amount of a compound as claimed in ~~any one of claims~~ claim 1 to 12, or a pharmaceutically acceptable salt thereof.